产前倍他米松预防新生儿呼吸窘迫综合征的群体药代与药效学研究
本研究纳入孕周>27周、至少接受单剂倍他米松预防RDS的孕妇,用Monolix分析母血、脐血和羊水中倍他米松的时程,建立二室模型。双胎妊娠使母体清除率增加28%,胎盘转运中位比为35%;调整孕周和双胎后,宫内低于可定量浓度(<1 ng/mL)的时间每增加1天,RDS风险增加(OR 1.10)。
要点
- 双胎妊娠使倍他米松母体清除率增加28%,需关注暴露差异。
- 胎盘转运中位比为35%(95%CI 0.11-0.67)。
- 宫内浓度<1 ng/mL时间每增1天,RDS风险OR 1.10。
核心结论
- 母体倍他米松暴露与RDS发生相关,宫内低于可定量浓度(<1 ng/mL)时间越长,RDS风险越高。
研究设计与样本
- 前瞻性纳入孕周>27周、至少接受单剂倍他米松预防RDS的孕妇,分析220份母血、56份脐血和26份羊水样本。
- 采用Monolix建立二室模型,含两个效应室并以速率转移常数连接,按70 kg孕晚期孕妇进行异速缩放。
主要发现
- 双胎妊娠使母体清除率增加28%。
- 胎盘转运中位比(胎儿/母体暴露比)为35%(95%CI 0.11-0.67)。
- 调整孕周和双胎妊娠后,宫内低于可定量浓度(<1 ng/mL)的时间每增加1天,RDS风险OR为1.10(95%CI 1.01-1.19,P<0.05)。
临床怎么用
- 可参考宫内浓度<1 ng/mL时间与RDS风险的关联,评估产前倍他米松暴露是否充分。
- 双胎妊娠孕妇倍他米松清除率增加28%,临床需关注其暴露可能偏低。
- 研究模拟了在不超标准总剂量的前提下维持更多胎儿浓度>1 ng/mL的给药方案,但未给出具体推荐剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite antenatal corticosteroids therapy, respiratory distress syndrome (RDS) is still a leading cause of neonatal morbidity and mortality in premature newborns. To date, the relationship between in utero fetal drug exposure and occurrence of RDS remains poorly evaluated. This study aims to describe the pharmacokinetics of betamethasone in pregnant women and to evaluate the transplacental drug transfer and administration scheme for the prevention of RDS. Pregnant women > 27 weeks' gestation and who received at least a single dose of betamethasone for prevention of RDS were enrolled. Maternal, cord blood, and amniotic fluid betamethasone time-courses were analyzed using the Monolix software. A total of 220 maternal blood, 56 cord blood, and 26 amniotic fluid samples were described by a two-compartment model with two effect compartments linked by rate transfer constants. Apparent clearances and volumes of distribution parameters were allometrically scaled for a 70 kg third trimester pregnant woman. The impact of a twin pregnancy was found to increase maternal clearance by 28%. Using a fetal-to-mother exposure ratio, the median (95% confidence interval (CI)) transplacental transfer of betamethasone was estimated to 35% (95% CI 0.11-0.67). After adjustment for gestational age and twin pregnancy, RDS was found to be associated to the time spent in utero below quantifiable concentrations (i.e., < 1 ng/mL): odds ratio of 1.10 (95% CI 1.01-1.19) per day increase (P < 0.05). Trying to take into account both efficacy and safety, we simulated different dosing schemes in order to maintain a maximum of fetuses above 1 ng/mL without exceeding the total standard dose.
引用
- Foissac F, Zheng Y, Hirt D, et al. Maternal Betamethasone for Prevention of Respiratory Distress Syndrome in Neonates: Population Pharmacokinetic and Pharmacodynamic Approach. Clin Pharmacol Ther. 2020. PMID: 32394434. doi:10.1002/cpt.1887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。